Arno Therapeutics to Collaborate With Veridex on Development of Diagnostic Test

Arno Therapeutics to Collaborate With Veridex on Development of Diagnostic
Test

FLEMINGTON, N.J., June 3, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc.
(OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the
development of oncology therapeutics, today announced that it has signed an
agreement with Veridex, LLC, a Johnson & Johnson company, to develop a
diagnostic test to detect the presence of activated progesterone receptors
(APRs) as a potential biomarker of anti-progestin activity in circulating
tumor cells (CTCs). The diagnostic will help identify patients whom could
potentially benefit from treatment with anti-progestins including onapristone,
an orally-administered, investigational type 1 progestin receptor antagonist
being developed by Arno.

CTCs are cancer cells that have detached from a solid tumor in the body and
are found in the bloodstream.The collaboration will allow Arno to utilize
Veridex's proprietary technology, CELLSEARCH®, which uses an advanced cell
separation technique called microfluidic separation integrated with innovative
magnetic sorting, to isolate CTCs and further analyze the cells for the
presence of APR.The CELLSEARCH® CTC System is the first and only
standardized, FDA-cleared, semi-automated system that captures, isolates, and
counts CTCs with a high level of sensitivity and specificity.

In pre-clinical studies, the presence of APR has shown to be predictive of
onapristone activity.Onapristone is believed to work by binding to
progesterone receptor proteins, thereby inhibiting dimerization,
phosphorylation and DNA transcription activity. Progesterone receptors (PRs)
are found in particular cells including those of the female reproductive
tissue and some cancers.^i The hormone progesterone binds to the receptors and
may cause the cells to grow.^i Preclinical studies have shown that PRs can
play a role as drivers of malignant cell growth in certain cancers.

"We are pleased to work with Veridex as we believe its pioneering technology
for isolating circulating tumor cells will serve as an important tool for the
continued development and study of onapristone," said Glenn Mattes, chief
executive officer and president, Arno Therapeutics."By taking blood samples
from patients rather than obtaining tissue samples, we hope to create a
simplified and less invasive process for identifying patients that are most
likely to benefit from treatment with onapristone."

The diagnostic test will be used in future clinical studies of onapristone,
which the company is planning to begin in the second half of 2013.

About Arno Therapeutics

Arno Therapeutics is a clinical stage biopharmaceutical company developing
innovative products for the treatment of cancer.Arno has exclusive worldwide
rights to develop and market three innovative anti-cancer product
candidates.These compounds are in clinical or preclinical development as
product candidates to treat hematologic malignancies and solid tumors.For
more information about the company, please visitwww.arnothera.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve
substantial risks and uncertainties. These statements are often, but not
always, made through the use of words or phrases such as "anticipates,"
"expects," "plans," "believes," "intends," and similar words or phrases. These
forward-looking statements include, without limitation, statements regarding
the timing, progress and anticipated results of the clinical development of
onapristone, Arno's use of the diagnostic test being developed with Veridex in
its planned Phase I trial of onapristone, as well as Arno's strategy, future
operations, outlook, milestones, future financial position, future financial
results, plans and objectives. We may not actually achieve these plans,
intentions or expectations and Arno cautions investors not to place undue
reliance on our forward-looking statements. Actual results or events could
differ materially from the plans, intentions and expectations disclosed in the
forward-looking statements we make. Various important factors could cause
actual results or events to differ materially from the forward-looking
statements that we make. Such factors include, among others, risks that the
results of clinical trials will not support our claims or beliefs concerning
the effectiveness of onapristone or any of our other product candidates, our
ability to finance the development of our product candidates, regulatory
risks, and our reliance on third party researchers and other collaborators.
Additional risks are described in the company's Annual Report on Form 10-K for
the year ended December 31, 2012. Arno is providing this information as of the
date of this press release and does not undertake any obligation to update any
forward-looking statements as a result of new information, future events or
otherwise.

^i National Cancer Institute. NCI Dictionary of Cancer Terms. Available at:
http://www.cancer.gov/dictionary?cdrid=423248. Last accessed: May 7, 2013.

CONTACT: The Ruth Group  
         Stephanie Carrington (investors)
         scarrington@theruthgroup.com
         (646) 536-7017  

         Caitlin Cox (media)
         ccox@theruthgroup.com
         (646) 536-7033

         Arno Therapeutics
         Glenn Mattes
         gm@arnothera.com 
         (862) 703-7176
 
Press spacebar to pause and continue. Press esc to stop.